These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Heparin complex formation with plasma fibrin-stabilizing factor in vitro]. Ul'ianov AM; Kudriashov BA; Liapina LA Biokhimiia; 1973; 38(6):1281-7. PubMed ID: 4802010 [No Abstract] [Full Text] [Related]
5. [Physicochemical properties of the diabetogenic factor and its complex with heparin]. Kudriashov BA; Ammosova IaM; Liapina LA; Ul'ianov AM Farmakol Toksikol; 1987; 50(3):49-52. PubMed ID: 3609278 [TBL] [Abstract][Full Text] [Related]
6. Chemistry and pharmacology of heparin. Ehrlich J; Stivala SS J Pharm Sci; 1973 Apr; 62(4):517-44. PubMed ID: 4121531 [No Abstract] [Full Text] [Related]
7. [Comparative study of the properties of a fibrinogen--heparin complex produced in vitro and one isolated from a plasma fraction of fibrinogen degradation products]. Kudriashov BA; Liapina LA; Zhitnikova ES; Kriukova MG Nauchnye Doki Vyss Shkoly Biol Nauki; 1979; (9):58-62. PubMed ID: 497299 [No Abstract] [Full Text] [Related]
8. [Formation of complexes of ATP, ADP and AMP with heparin in vitro]. Liapina LA; Kudriashov BA Nauchnye Doki Vyss Shkoly Biol Nauki; 1977; (9):22-6. PubMed ID: 911953 [No Abstract] [Full Text] [Related]
9. [Electron microscopic study of the depolymerization process on unstabilized fibrin as affected by urea or monochloracetic acid]. Ul'ianov AM; Zhitnikova ES Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (8):59-63. PubMed ID: 6226322 [TBL] [Abstract][Full Text] [Related]
10. [Role of heparin in inhibiting fibrin formation]. Rozenfel'd MA; Kleĭmenov AN; Meshkov BB; Gershkovich KB; Shimkevich LL Izv Akad Nauk SSSR Biol; 1984; (1):47-54. PubMed ID: 6707314 [No Abstract] [Full Text] [Related]
11. [Interaction of poly-2-methyl-5-vinyl-N-ethylpyridinium bromide and heparin studied by means of ultraviolet and infrared spectroscopy]. Zubakova LB; Gandurina LV; Shabanova NV; Smirnov AV; Prosvetova NK; Frumin LE; Makarova GV; Kas''ianenko VV; vlasov LG Polim Med; 1977; 7(4):255-63. PubMed ID: 614540 [TBL] [Abstract][Full Text] [Related]
12. Failure of heparin, epsilon aminocaproic acid, or both agents to prevent increased fibrinogen levels after endotoxin in rabbits. Logan LJ; Rapaport SI; Kuefler P Proc Soc Exp Biol Med; 1973 Jan; 142(1):321-3. PubMed ID: 4566763 [No Abstract] [Full Text] [Related]
14. [Modern data on the chemistry and physiology of fibrinogen]. Andreenko GV Usp Sovrem Biol; 1974; 77(1):51-69. PubMed ID: 4282801 [No Abstract] [Full Text] [Related]
15. Chemistry of heparin and low molecular weight heparin. Nielsen JI; Ostergaard P Acta Chir Scand Suppl; 1988; 543():52-6. PubMed ID: 2847458 [No Abstract] [Full Text] [Related]
16. Physicochemical properties of heparin, and its interaction with Cu(II) and calcium in relation to anticoagulation. Stivala SS Fed Proc; 1977 Jan; 36(1):83-8. PubMed ID: 12019 [No Abstract] [Full Text] [Related]
17. [Fibrinolysis in the blood of animals exposed to the chronic per os use of a heparin-urea complex]. Kudriashov BA; Liapina LA Farmakol Toksikol; 1977; 40(5):559-63. PubMed ID: 923778 [TBL] [Abstract][Full Text] [Related]
18. [Heparin-urea complex and its biological properties]. Liapina LA; Kudriashov BA Nauchnye Doki Vyss Shkoly Biol Nauki; 1975; (10):46-9. PubMed ID: 1203401 [No Abstract] [Full Text] [Related]
19. [Effect of heparin and epsilon-aminocaproic acid on the development of experimental arteriosclerosis]. Khalfen ESh; Savinich BV Kardiologiia; 1969 May; 9(5):15-8. PubMed ID: 5805771 [No Abstract] [Full Text] [Related]